Pharmafile Logo

News and Press Releases

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

Celonic Group and CARBOGEN AMCIS Announce Strategic Alliance to Deliver Fully Integrated ADC Development and Manufacturing Platform

7 October 2025 -- Basel, Switzerland -- CELONIC GROUP, one of the leading “pureplay” Biologics CDMO, and the Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API)...

Category: BioManufacturing, Clinical Trials, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 7, 2025

CARBOGEN AMCIS
info@carbogen-amcis.com
Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V.,...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: September 25, 2025

Synaffix
admin.synaffix@lonza.com
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands

eXmoor Pharma and Siam Bioscience form strategic partnership to establish leading Cell and Gene Therapy services in Southeast Asia

23 September 2025 -- Bristol, UK and Bangkok, Thailand -- eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 23, 2025

eXmoor Pharma
info@exmoorpharma.com
Britannia Road, Patchway, Bristol, BS34 5TA

HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure

7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025

Heartbeat.Bio
office@heartbeat.bio
Vienna Biocenter 6 Dr. Bohr-Gasse 7 A-1030 Vienna Austria

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

4 April 2025 -- Valby, Denmark -- H. Lundbeck A/S (Lundbeck) to present positive interim results from the PACIFIC trial open-label extension investigating bexicaserin, in addition to new analyses from...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 4, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 2, 2025

Neumora
investors@neumoratx.com
490 Arsenal Way, Suite 200 Watertown, MA 02472

Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics

Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities 29 October 2024 -- New York, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: October 29, 2024

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA